| DBV TECHNOLOGIES ADR |
| USA |
| Gesundheit |
| US23306J3095 / A40WEX |
| DBV1 (Frankfurt) / DBVT (NASDAQ) |
| FRA:DBV1, ETR:DBV1, DBV1:GR, NASDAQ:DBVT |
| - |
| https://dbv-technologies... |
|
DBV Technologies is a clinical-stage biopharmaceutical company headquartered in Bagneux, France, specializing in immunotherapy treatments for food allergies. The company is known for developing the Viaskin patch, a proprietary transdermal technology ..
>Volltext.. |
| 1043.12 Mio. EUR |
| 893.7 Mio. EUR |
| - |
| -117.32 Mio. EUR |
| -127.65 Mio. EUR |
| -4.57 EUR |
| 18.79 Mio. EUR |
| 168.21 Mio. EUR |
| -105.31 Mio. EUR |
| 3.35 |
| - |
| -29.54% |
| - |
| - |
| - |
| - |
| DBV TECHNOLOGIES ADR, DBV TECHNOLOGIES, DBV TECH |
| 05.04.26 |
|